Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment
/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...
United States Hebrew University Allen Baharaff Galmed Pharmaceuticals Ltd Artificial Intelligence Galmed Pharmaceuticals
Source: prnewswire.com